معرفی
Frank Leebeek is a Full Professor in the Department of Hematology at Erasmus MC, a leading academic medical center in the Netherlands. His research is centered on bleeding disorders, particularly hemophilia and von Willebrand disease, with a strong focus on molecular mechanisms, clinical phenotypes, and novel therapies.
His research interests include the pathophysiology of von Willebrand factor, pharmacokinetics of clotting factors, platelet dysfunction, and genetic determinants of bleeding severity. He investigates both inherited and acquired coagulation disorders, aiming to improve diagnosis, treatment, and quality of life for patients.
The recent articles highlight a strong trend toward translational research, combining basic science (e.g., gene editing, siRNA) with clinical studies (e.g., patient cohorts, bleeding phenotypes). His work bridges molecular hematology and clinical practice, contributing to both diagnostic innovation and therapeutic development.
Frank Leebeek has supervised 29 academic works, indicating a significant role in mentoring the next generation of researchers. He collaborates widely through consortia such as the SYMPHONY consortium, TiN study group, and Willebrand in the Netherlands (WiN) study group, reflecting a networked and team-based research approach. Although no specific grants are listed, his extensive publication output suggests sustained funding and research activity.
He is involved in multiple collaborative research teams focused on thrombosis and hemostasis, including national and international consortia. These teams work on standardizing care, understanding disease variability, and developing targeted therapies, particularly for rare bleeding disorders.
